Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
endometrial cancer
microsatellite instability
mismatch repair deficiency
platinum-based chemotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Jul 2023
15 Jul 2023
Historique:
received:
10
06
2023
revised:
04
07
2023
accepted:
14
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
There is poor evidence regarding sensitivity to chemotherapy in endometrial cancer (EC) based on microsatellite instability (MSI)/mismatch repair (MMR) status. The RAME study is a retrospective analysis aiming to assess response to chemotherapy in MSI-high (h)/deficient (d) MMR and MSI-low (l)/proficient (p) MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease and progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent disease. A total of 312 patients treated between 2010 and 2022 in four high-volume Multicenter Italian Trial in Ovarian cancer and gynecological malignancies (MITO) centers were selected. In total, 239 patients had endometrioid EC (76.6%), 151 had FIGO stage I at diagnosis (48.9%) and 71 were MSI-h/dMMR (22.8%). Median age was 65 (range 31-91) years. Among patients with localized disease, median RFS was 100.0 months (95% CI 59.4-140.7) for MSI-l/pMMR and 120.9 months (60.0-181.8) for MSI-h/dMMR ( Patients with metastatic MSI-h/dMMR EC receiving first-line chemotherapy had a significantly worse OS.
Sections du résumé
BACKGROUND
BACKGROUND
There is poor evidence regarding sensitivity to chemotherapy in endometrial cancer (EC) based on microsatellite instability (MSI)/mismatch repair (MMR) status.
METHODOLOGY
METHODS
The RAME study is a retrospective analysis aiming to assess response to chemotherapy in MSI-high (h)/deficient (d) MMR and MSI-low (l)/proficient (p) MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease and progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent disease.
RESULTS
RESULTS
A total of 312 patients treated between 2010 and 2022 in four high-volume Multicenter Italian Trial in Ovarian cancer and gynecological malignancies (MITO) centers were selected. In total, 239 patients had endometrioid EC (76.6%), 151 had FIGO stage I at diagnosis (48.9%) and 71 were MSI-h/dMMR (22.8%). Median age was 65 (range 31-91) years. Among patients with localized disease, median RFS was 100.0 months (95% CI 59.4-140.7) for MSI-l/pMMR and 120.9 months (60.0-181.8) for MSI-h/dMMR (
CONCLUSIONS
CONCLUSIONS
Patients with metastatic MSI-h/dMMR EC receiving first-line chemotherapy had a significantly worse OS.
Identifiants
pubmed: 37509300
pii: cancers15143639
doi: 10.3390/cancers15143639
pmc: PMC10377998
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Gynecol Oncol. 2008 May;109(2):250-4
pubmed: 18299146
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):197-203
pubmed: 17291253
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Mod Pathol. 2015 Jun;28(6):836-44
pubmed: 25720322
Int J Gynecol Cancer. 2020 Nov;30(11):1738-1747
pubmed: 32771986
J Clin Oncol. 2007 May 20;25(15):2042-8
pubmed: 17513808
Prz Menopauzalny. 2016 Jun;15(2):63-8
pubmed: 27582678
Semin Oncol Nurs. 2019 Apr;35(2):157-165
pubmed: 30867105
Cancer Control. 2009 Jan;16(1):14-22
pubmed: 19078925
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
Int J Gynecol Cancer. 2021 Apr;31(4):594-604
pubmed: 33082238
J Clin Oncol. 2020 Nov 20;38(33):3841-3850
pubmed: 33078978
Front Oncol. 2022 Dec 15;12:1004469
pubmed: 36591511
Nat Rev Dis Primers. 2021 Dec 9;7(1):88
pubmed: 34887451
Ann Oncol. 2018 Feb 1;29(2):424-430
pubmed: 29190319
Gynecol Oncol Res Pract. 2016 Dec 13;3:14
pubmed: 27999680
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35064011
Lancet Oncol. 2018 Mar;19(3):295-309
pubmed: 29449189
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
Int J Gynecol Pathol. 2020 Jan;39(1):26-35
pubmed: 30741844
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
J Clin Oncol. 2022 Mar 1;40(7):752-761
pubmed: 34990208
Am Soc Clin Oncol Educ Book. 2017;37:435-442
pubmed: 28561715
Clin Cancer Res. 2018 Dec 1;24(23):5939-5947
pubmed: 30068706
N Engl J Med. 2023 Jun 8;388(23):2159-2170
pubmed: 36972022
N Engl J Med. 2023 Jun 8;388(23):2145-2158
pubmed: 36972026
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Int J Cancer. 2022 Jan 1;150(1):7-17
pubmed: 34398969